Table 3.
Prophylactic and therapeutic administration of mozavaptan or etanercept in PKD2(ws25 /-)micea
| Treatment | Age at treatment | N | Kidney weight (% of bw) | Cyst number (per field) | BUN (mg/dL) | Urine production b (mL/mouse) | Water consumption b (mL/mouse/day) |
|---|---|---|---|---|---|---|---|
| Vehicle |
13 weeks |
14 |
1.85 ± 0.17 |
6.7 ± 0.7 |
20.6 ± 1.2 |
0.99 ± 0.20 |
4.0 ± 0.04 |
| Mozavaptan (0.1%) |
13 weeks |
11 |
1.74 ± 0.11 |
6.9 ± 1.1 |
23.6 ± 2.0 |
4.93 ± 1.64c |
11.1 ± 0.35c |
| Etanercept (5 mg/kg) |
13 weeks |
15 |
1.75 ± 0.09 |
6.5 ± 0.8 |
20.1 ± 1.5 |
NA |
4.0 ± 0.06 |
| Vehicle |
4 weeks |
15 |
1.96 ± 0.15 |
7.0 ± 0.7 |
24.8 ± 2.7 |
NA |
6.1 ± 0.18 |
| Mozavaptan (0.05%) |
4 weeks |
15 |
1.78 ± 0.07 |
7.7 ± 0.8 |
26.1 ± 2.1 |
NA |
9.6 ± 0.35c |
| Etanercept (10 mg/kg) |
4 weeks |
15 |
1.84 ± 0.2 |
5.5 ± 0.6 |
21.9 ± 1.6 |
NA |
5.9 ± 0.16 |
| Etanercept (5 mg/kg) | 4 weeks | 15 | 1.77 ± 0.17 | 6.2 ± 0.7 | 23.2 ± 2.0 | NA | 5.8 ± 0.18 |
aData shown are group average ± SEM.
bUrine production over 4 hours monitoring in metabolic cage; separate measure of daily water consumption, by bottle weighing.
cComparison between vehicle and treatment group, p<0.05.